Common neural substrates for the addictive properties of nicotine and cocaine

Science

Volumn 275, Issue 5296, 1997, Pages 83-86

  Pich, Emilio Merlo ^a   Pagliusi, Sonia R ^a   Tessari, Michela ^b   Talabot Ayer, Dominique ^a   Van Huijsduijnen, Rob Hooft ^a   Chiamulera, Christian ^b  

^a GLAXOSMITHKLINE   (United States)

^b GSK   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; NICOTINE; PROTEIN C FOS;

AMYGDALOID NUCLEUS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; DRUG SELF ADMINISTRATION; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REINFORCEMENT;

AMYGDALA; ANIMALS; BRAIN; BRAIN MAPPING; COCAINE; DNA; NEOSTRIATUM; NEURONS; NICOTINE; NUCLEUS ACCUMBENS; OPIOID-RELATED DISORDERS; PREFRONTAL CORTEX; PROTO-ONCOGENE PROTEINS C-FOS; RATS; REINFORCEMENT (PSYCHOLOGY); SELF ADMINISTRATION; SUBSTANCE-RELATED DISORDERS; TRANSCRIPTION FACTOR AP-1;

EID: 0031016618     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.275.5296.83     Document Type: Article

References (32)

1. J. H. Jaffe and M. Kanzler, Natl. Inst. Drug Abuse (NIDA) Res. Monogr. Ser. 23 (1979), p. 4; I. P. Stolerman and M. J. Jarvis, Psychopharmacology 117, 2 (1995).
2. J. H. Jaffe and M. Kanzler, Natl. Inst. Drug Abuse (NIDA) Res. Monogr. Ser. 23 (1979), p. 4; I. P. Stolerman and M. J. Jarvis, Psychopharmacology 117, 2 (1995).
3. P. Calabresi, M. G. Lacey, R. A. North, Brit. J. Pharmacol. 98, 135 (1989); M. Nisell, G. G. Nomikos, T. H. Svensson, Synapse 16, 36 (1994); F. Pontieri et al., Nature 382, 255 (1996).
4. P. Calabresi, M. G. Lacey, R. A. North, Brit. J. Pharmacol. 98, 135 (1989); M. Nisell, G. G. Nomikos, T. H. Svensson, Synapse 16, 36 (1994); F. Pontieri et al., Nature 382, 255 (1996).
5. P. Calabresi, M. G. Lacey, R. A. North, Brit. J. Pharmacol. 98, 135 (1989); M. Nisell, G. G. Nomikos, T. H. Svensson, Synapse 16, 36 (1994); F. Pontieri et al., Nature 382, 255 (1996).
6. N. E. Goeders and J. E. Smith, Science 221, 773 (1983); G. F. Koob and F. E. Bloom, ibid. 242, 715 (1988); G. Di Chiara, Drug Alcohol Depend. 38, 95 (1995).
7. N. E. Goeders and J. E. Smith, Science 221, 773 (1983); G. F. Koob and F. E. Bloom, ibid. 242, 715 (1988); G. Di Chiara, Drug Alcohol Depend. 38, 95 (1995).
8. N. E. Goeders and J. E. Smith, Science 221, 773 (1983); G. F. Koob and F. E. Bloom, ibid. 242, 715 (1988); G. Di Chiara, Drug Alcohol Depend. 38, 95 (1995).
9. W. A. Corrigal and K. M. Cohen, Psychopharmacology 99. 473 (1989); W. A. Corrigal, K. B. J. Franklin, K. M. Choen, P. B. S. Clarke, ibid. 107, 285 (1992).
10. W. A. Corrigal and K. M. Cohen, Psychopharmacology 99. 473 (1989); W. A. Corrigal, K. B. J. Franklin, K. M. Choen, P. B. S. Clarke, ibid. 107, 285 (1992).
11. M. Tessari, E. Valerio, C. Chiamulera, P. M. Beardsley, Psychopharmacology 121, 282 (1995).
12. S. M. Sagar, F. R. Sharp, T. Curran, Science 240, 1328 (1988); S. M. Morgan and T. Curran, Annu. Rev. Neurosci. 14, 421 (1991).
13. S. M. Sagar, F. R. Sharp, T. Curran, Science 240, 1328 (1988); S. M. Morgan and T. Curran, Annu. Rev. Neurosci. 14, 421 (1991).
14. S. T. Young, L. J. Porrino, M. J. ladarola, Proc. Natl. Acad. Sci. U.S.A. 88, 1291 (1991); B. T. Hope, B. Kosofski, S. H. Hyman, E. J. Nestler, ibid. 89, 5764 (1992).
15. S. T. Young, L. J. Porrino, M. J. ladarola, Proc. Natl. Acad. Sci. U.S.A. 88, 1291 (1991); B. T. Hope, B. Kosofski, S. H. Hyman, E. J. Nestler, ibid. 89, 5764 (1992).
16. T. Ren and S. M. Sagar, Brain Res. Bull. 29, 589 (1992); Y. Pang, H. Kiba, A. Jayaraman, Mol. Brain Res. 20, 162 (1993).
17. T. Ren and S. M. Sagar, Brain Res. Bull. 29, 589 (1992); Y. Pang, H. Kiba, A. Jayaraman, Mol. Brain Res. 20, 162 (1993).
18. B. T. Hope et al., Neuron 13, 1235(1994).
19. Rats were anesthetized and transcardiacally perfused as described (7, 8). Cryosections (35 μm) were sequentially incubated with antibodies against FRAs (7) (dilution, 1:4000), and tyrosine hydroxylase (TH; dilution 1:500) (Chemicon) was used to stain DA terminals. Detection was performed with avidin-biotin-peroxidase complex (Vector Laboratories), followed by diaminobenzidine for TH and nickel enhancement for FRA signals. The number of positive nuclei was measured within a squared field area of 270 × 270 μm with the use of the IBAS image analyses system (Zeiss, Germany). Each area was measured in four adjacent coronal sections, and the results were averaged. For details, see M. Zoli et al., Neurochem. Int. 16, 383 (1990).
20. All rats were kept on a restricted diet regime (85% of the normal body weight). Nicotine (0.03 mg per kilogram of body weight) was delivered in a volume of 22 μl per infusion, cocaine (0.25 mg/kg) at 100 μl per infusion, and saline at 22 μl per infusion. These doses were selected among those that can maintain stable self-administration in rats [B. C. Caine and G. F. Koob, J. Pharmacol. Exp. Ther. 270, 209 (1994)] (4, 5). No claim for equipotency of the two drugs was made because direct comparison of the reinforcing effects of cocaine and nicotine requires further studies. Thus, no direct statistical comparison was planned between nicotine and cocaine self-administration groups. Stable baseline performance was defined when the rate of lever pressing between three consecutive sessions did not vary more than 20%.
21. D. D. Flemmer and S. C. Disalver, Pharmacol. Biochem. Behav. 34, 261 (1989); X. M. Yang, A. L. Gorman, A. J. Dunn, N. E. Goeders, ibid. 41, 643 (1992).
22. D. D. Flemmer and S. C. Disalver, Pharmacol. Biochem. Behav. 34, 261 (1989); X. M. Yang, A. L. Gorman, A. J. Dunn, N. E. Goeders, ibid. 41, 643 (1992).
23. Brain structures were microdissected from cryostat sections (300 mm) according to M. Palkowitz and M. J. Brownstein, IBRO Handb. Ser. Methods Neurosei. 2, 1 (1983). Crude nuclear extracts, probe preparation, and bandshift assays were performed as described [ M. Becker-André et al., Eur. J. Biochem. 206, 401 (1992)]. The AP-1 probe (GCC GCA AGT GAC TCA GCG CGG G and its complement) was derived from the human metalloprotein ll A promoter (9).
24. Brain structures were microdissected from cryostat sections (300 mm) according to M. Palkowitz and M. J. Brownstein, IBRO Handb. Ser. Methods Neurosei. 2, 1 (1983). Crude nuclear extracts, probe preparation, and bandshift assays were performed as described [ M. Becker-André et al., Eur. J. Biochem. 206, 401 (1992)]. The AP-1 probe (GCC GCA AGT GAC TCA GCG CGG G and its complement) was derived from the human metalloprotein ll A promoter (9).
25. Acute administration of nicotine in saline rats during the last session did not change AP-1 binding in any brain region when compared with that in saline rats (17).
26. D. S. McGehee, M. J. Heath, S. Gelber, P. Devay, L. W. Role, Science 269, 1692 (1995).
27. J. E. Henningfield, K. Miyasato, D. R. Jasinski, Pharmacol. Biochem. Behav. 19,887 (1983); M. W. Fischman and C. R. Schuster, Fed. Proc. 41, 241 (1982).
28. J. E. Henningfield, K. Miyasato, D. R. Jasinski, Pharmacol. Biochem. Behav. 19,887 (1983); M. W. Fischman and C. R. Schuster, Fed. Proc. 41, 241 (1982).
29. E. Merlo Pich et al., data not shown.
30. L. W. Swanson Brain Maps: Structures of the Rat Brain (Elsevier, Amsterdam, 1992).
31. When the mutant oligonucleotide (GCC GCA ATG TCA GAC TAG CGG G) was used, no bands were detected (17).
32. We thank M. ladarola for providing the antibody to FRAs; R. A, North for discussing the manuscript; S. Catsicas, J. Knowles, D. Trist, and E. Ratti for constant support; and S. DeVevey and E. Valerio for excellent technical assistance. All animal procedures conformed to the Guide for the Care and Use of Laboratory Animals (NIH). Part of these data was presented at the Society for Neuroscience meeting [C. Chiamulera et al., Soc. Neurosci. Abstr. 21, 722 (1995)].